NeuraSim’s Journey: Transforming Amblyopia Treatment with SISFS and RICH Support

Pioneering VR-Based Solutions for Vision Care

Foundations of Growth

Introduction

NeuraSim’s journey has been significantly shaped by the unwavering support of Startup India and Research and Innovation Circle of Hyderabad (RICH). Through the Startup India Seed Fund Scheme (SISFS), we successfully secured ₹45 lakhs, providing a vital foundation for our growth.
A Leap Forward: ₹45 Lakhs Seed Funding from SISFS Fuels NeuraSim’s Vision for Innovation

Multicentric Randomized Controlled Clinical Trials

We have initiated multicentric randomized controlled clinical trials (Gold standard study) across esteemed institutions, including LV Prasad Eye Institute, Aravind Eye Care System, and Dr. Shroff’s Charity Eye hospitals. These trials aim to demonstrate the clinical efficacy of our pioneering VR-based device—a transformative solution for amblyopia treatment.
Pioneering Excellence: Multicentric Clinical Trials Clinical Trials at Leading Institutions Validate NeuraSim’s VR-Based Amblyopia Treatment

Outcomes and Future Impact.

The outcome of this SISFS-supported study will aid in obtaining national and international regulatory approvals, enhancing market reach, and revolutionizing amblyopia treatment globally.

Worldwide Impact